Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05069558

Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Alberta Mazankowski Heart Institute, Edmonton, Alberta, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects with a PFO and cryptogenic stroke:

  • PFO defined as visualization of microbubbles (during Trans Esophageal Echo (TEE)) in the left atrium within three cardiac cycles of right atrial opacification at rest and/or with Valsalva.
  • Cryptogenic stroke defined as a stroke of unknown cause.
  • Stroke defined as an acute focal neurological deficit, presumed to be due to focal ischemia, and either:
  • Symptoms persisting ≥24 hours OR
  • Symptoms persisting <24 hours with Magnetic Resonance Imaging (MRI) or Computer Tomography (CT) findings of a new, neuroanatomically relevant, cerebral infarct.

Exclusion criteria

  • Age < 18 years
  • Myocardial Infarction (MI) or unstable angina within 6 months.
  • Severe mitral valve stenosis, severe aortic valve stenosis, or severe regurgitation.
  • Left Ventricle Ejection Fraction (LVEF) <35%.
  • Uncontrolled hypertension or diabetes mellitus despite medications.
  • Subjects contraindicated for aspirin or clopidogrel.
  • Presence of other comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results.
  • Qualifying stroke with Modified Rankin score >3.
  • Anatomy in which the device would interfere with intracardiac or vascular structures.
  • Life expectancy < 2 years.
  • Participation in another clinical study that can interfere with the results of this study
  • Exclusion for patients with known causes of ischemic stroke:
  • Atrial fibrillation/atrial flutter (chronic or intermittent).
  • Left Ventricle (LV) aneurysm, intracardiac thrombus, or tumor.
  • Mitral or aortic valve vegetation or prosthesis.
  • Aortic arch plaques protruding >4 mm into the lumen.
  • Atherosclerosis or arteriopathy of intra- or extracranial vessels with >50% diameter stenosis in the artery supplying the infarcted territory.
  • Another cause of right-to-left shunting (e.g., an Atrial Septal Defect (ASD) or a fenestrated atrial septum).
  • Presence of an arterial hypercoagulable state.
  • Lacunar infarct probably due to intrinsic small vessel as the qualifying event, defined as an ischemic stroke in the distribution of a single, small deep penetrating vessel in a patient with any of the following:
  • A history of hypertension (except in the first week post stroke).
  • A history of diabetes mellitus.
  • Age ≥50 years.
  • MRI or CT with leukoaraiosis greater than symmetric, well-defined periventricular caps, or bands (European Task Force on Age-Related White Matter Changes rating scale score >0).
  • Arterial dissection as the qualifying event.

Treatment and study plan

Investigational PFO Closure Device

Device

Occlutech Flex II PFO Closure Device

Standard of Care PFO Closure Device

Device

Amplatzer PFO Occluder and Gore Cardioform PFO Occluder

Primary outcomes

  1. Effective Closure Rate of PFO

    Time frame: Twelve Months

Secondary outcomes

  1. Non-Fatal Recurrent Stroke

    Time frame: Enrollment to 12 Months

Other outcomes

  1. Safety: Device and Procedure Related Serious Adverse Events

    Time frame: Enrollment to Twelve Months, Annually thereafter.

Sponsors and collaborators

Lead sponsor

Occlutech International AB

Industry

Registry information

Official study title

Prospective Randomized Multi-center Controlled Clinical Investigation Comparing Patent Foramen Ovale (PFO) Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

Acronym: OCCLUFLEX

Important dates

Study start
2022
Primary completion
2025
Study completion
2029
First posted
Oct 6, 2021
Registry last updated
May 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.